From DCAT Value Chain Insights (VCI)
Kaneka Eurogentec, a Liège Belgium-headquartered contract development and manufacturing organization, has approved the construction of a new GMP biomanufacturing facility adjacent to its current facility and equipped with a 2,200-liter fermenter. The expansion will allow for the large-scale production of biopharmaceuticals, including recombinant proteins, antibody fragments, and plasmid DNA.
The multi-product facility will include the capability for large-scale production using Eurogentec technologies such as the production of x proteins by secretion from yeasts and the production of kilo-scale plasmid DNA for viral and non-viral gene and cell therapies. This expansion will be complementary to the company's current capabilities and together will provide small- and industrial-scale production. The expansion will result in the hiring of 40 full time scientific staff trained in the production of GMP therapeutic products.
Construction is expected to start in the autumn of 2017.
Source: Kaneka Eurogentec
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription